Patient P-02619
Synthetic patientMETA-24 · Day 156 · 55–64 · M · baseline S17Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Favorable
Discontinuation risk
41%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S17
- Day 40 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 40.
Primary contributors, last 14 days
- GI instability+16
- Treatment adherence-7
- Inflammatory activity+5
- Nutritional resilience-3
- Toxicity-3
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable69 min
improving · +4.1 vs previous 14 d
Sleep duration
Wearable8.1 h
stable · +0.0 vs previous 14 d
Energy level
Daily log5.3/10
stable · -0.0 vs previous 14 d
Steps
Wearable6,663
improving · +542 vs previous 14 d
GI burden
Companion24.2/100
worsening · +0.8 vs previous 14 d
Adherence
Companion79.7 %
stable · +2.7 vs previous 14 d
Sleep quality
Wearable65.6/100
stable · -0.6 vs previous 14 d
Glucose, CGM daily mean
CGM133 mg/dL
stable · -1.0 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 62 from the failing basin, 43 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -3.9 next day on high-intake days · n 19
Would not help
- BR-03 Behavioural Recommendationonly 22% improved among 9 similar
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-3.9supporter · 95%
- Dietary fat load-1.6no signal · 53%
- Histamine load+1.3no signal · 47%
- Alcohol-1.2no signal · 35%
- Caffeine+0.8no signal · 20%
- Ultra-processed food+0.6no signal · 19%
- Insoluble fibre-0.2no signal · 15%
- Simple carbohydrates-0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
DNA
Fictional pharmacogenomic panel
- CYP2D6 Normal metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3.4 · butyrate capacity 65/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 61 ms
- Sleep
- 8.0 h
- Steps
- 6,085
- Resting HR
- 68 bpm
Daily log: GI score 24, nutritional resilience 63, adherence 80.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02214 | 27% | S08 | SC-12 | no change | 69 |
| P-02293 | 28% | S15 | HY-01 | no change | 68 |
| P-02095 | 28% | S08 | — | — | 66 |
| P-02476 | 27% | S05 | — | — | 65 |
| P-02286 | 27% | S10 | — | — | 65 |
| P-02491 | 27% | S09 | DT-01 | no change | 65 |
| P-02423 | 27% | S10 | — | — | 65 |
| P-02044 | 29% | S03 | — | — | 64 |
| P-02483 | 28% | S06 | BR-03 | no change | 64 |
| P-02579 | 29% | S09 | — | — | 64 |
| P-02437 | 27% | S01 | — | — | 64 |
| P-02191 | 27% | S18 | — | — | 63 |